FDA opens the door for VB0004’s US regulatory pathway
Vectus Biosystems Limited (ASX: VBS) has announced that the US Food and Drug Administration (FDA) has granted the company’s request for a pre-Investigational New Drug (pre-IND) Type B meeting for VB0004 in Idiopathic Pulmonary Fibrosis (IPF). The FDA’s written responses regarding Vectus’ proposed US development programme are expected to be received by mid-November 2026.
Vectus is now finalising and submitting its meeting package to the FDA in conjunction with its US Regulatory Agent, Cardinal Health Regulatory Services. VB0004 is described as a first-in-class oral vasoactive intestinal peptide (VIP)-mimetic and natriuretic peptide receptor C (NPR-C)-agonist in development for the treatment of IPF. The company has completed a Phase Ia clinical study in healthy volunteers, establishing a favourable safety and pharmacokinetic profile. US regulatory activities are now underway to establish the foundation for future clinical development in the US.
Dr Tara Speranza, CEO & CTO
“FDA granting of our pre-IND meeting request represents an important step in progressing the US regulatory pathway for VB0004 and provides us with the opportunity to obtain formal guidance on our proposed development program in IPF.”
When big ASX news breaks, our subscribers know first
What is a pre-IND Type B meeting and why does it matter?
A pre-IND meeting is a formal consultation with the FDA that takes place before a company submits an Investigational New Drug (IND) application, which is required to begin clinical trials in the United States. It gives companies the opportunity to seek regulatory guidance on their proposed development programme before committing to a full IND submission.
The Type B classification is one of three FDA meeting categories and is among the more substantive forms of engagement available to clinical-stage companies, typically covering IND submissions, clinical holds, and end-of-phase matters. Importantly, the FDA’s decision to grant this request is not automatic; it signals the agency’s formal willingness to engage with Vectus’ programme.
For investors, written FDA guidance at this stage can help shape clinical trial design, reduce regulatory risk, and clarify the pathway toward US trials. The pre-IND process for VB0004 now follows these steps:
- Company submits meeting request
- FDA grants request (this milestone)
- Company finalises and submits meeting package
- FDA provides written responses (expected mid-November 2026)
VB0004 and the IPF opportunity
IPF is described in the announcement as a progressive and often fatal lung disease with significant unmet medical need. VB0004 is Vectus’ lead compound targeting this indication, characterised as a first-in-class oral vasoactive intestinal peptide (VIP)-mimetic and natriuretic peptide receptor C (NPR-C)-agonist.
In pre-clinical models, VB0004 has demonstrated the ability to reverse established fibrosis. The completed Phase Ia study in healthy volunteers established a favourable safety and pharmacokinetic profile, providing the clinical foundation underpinning the current US regulatory push.
Beyond IPF, Vectus is advancing a broader pipeline of antifibrotic assets targeting cardiovascular, renal, and liver fibrosis. The commercial potential of this platform has been externally validated through a licensing agreement with an international biotechnology company for one of Vectus’ renal fibrosis assets, outlining a pathway for potential future milestone and royalty revenues.
The asset-for-equity deal with XORTX Therapeutics, completed in April 2026, transferred the VB4-P5 renal compound in exchange for a 9.9% stake in the Nasdaq-listed biotech, concentrating internal resources on VB0004 as the company’s primary development priority.
| Asset | Indication | Stage | Geography | Status |
|---|---|---|---|---|
| VB0004 | Idiopathic Pulmonary Fibrosis (IPF) | Phase Ia complete | US (regulatory activities underway) | Pre-IND Type B meeting granted |
| Renal fibrosis asset | Renal fibrosis | Licensing stage | International | Licensed to international biotech; milestone and royalty pathway |
| Pipeline assets | Cardiovascular and liver fibrosis | Preclinical / pipeline | Not specified | In development |
What’s next for Vectus and VB0004
The immediate priority for Vectus is finalising and submitting its meeting package to the FDA. Written responses from the agency are expected by mid-November 2026, and the company has stated this feedback will help inform the next stages of VB0004’s clinical and regulatory development.
Dr Speranza noted the company is “We are now focused on finalising our meeting package, with the FDA’s written responses expected in November 2026,” adding that “this feedback will help inform the next stages of VB0004’s clinical and regulatory development as we work towards advancing the program.”
Vectus’ broader strategic ambition, as stated in the announcement, is to create shareholder value through the advancement, partnering, and commercialisation of innovative therapies that address significant unmet needs in fibrotic disease.
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news straight to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ subscribers already getting the edge on market-moving announcements the moment they drop. Click the “Free Alerts” button at StockWire X to start receiving alerts today.